PLTTECH Raises ￥10M in Pre-A Round of Financing

According to VCBeat, Zhejiang Puluoting Healthcare Technology Co., Ltd. ("PLTTECH") announced that it raised over 10 million yuan in a Pre-A round of financing, led by Zheshang Venture Capital, with participation from angel round investor Zhejiang Kefa Capital. North Beta Capital acted as the exclusive financial advisor in the latest round. Proceeds from this round will be mainly used to get the samples of several R&D pipelines of PLTTECH and promote the multi-center verification before clinical registration.

Prior to this, PLTTECH completed a ￥10 million angel round of financing in 2017, with exclusive investment from Zhejiang Kefa Capital.

Founded in 2015, PLTTECH is a high-tech company focused on the single-cell analysis for precise research. It is also a rare enterprise in the domestic which can provide the comprehensive solution of mass cytometry (CyTOF) for large-scale commercialization.

As the first batch of the enterprises that introducing CyTOF to China, with two years of independent R&D and optimization, PLTTECH successfully expanded the original 35 detection channels to 42 channels in the CyTOF instrument, reached the highest level nationwide, greatly improving the single-cell sequencing dimension of CyTOF that can be used. 

At present, PLTTECH has standardized and integrated all processes of CyTOF, and used more detection reagents and consumables to take place the imported products, which greatly reduces the cost of detection. At the same time, the company also established a professional team, using unsupervised learning, algorithm, a variety of propriety analysis software and diversified data analysis to make bioinformatics analysis.

ZSVC has currently managed more than 30 VC/PE funds, NEEQ funds, private placement funds, mergers and acquisitions funds, with AUM of approximately 40 billion yuan.

ZSVC mainly invested in big health, big consumption, new economy, new manufacturing and other fields.

ZJKF Capital focuses on angel investment and VC/PE investment. At present, the company manages 15 funds with AUM of 10 billion yuan. It mainly invests in healthcare, high-end manufacturing, artificial intelligence (AI), big data, cloud computing, new materials, new energy and other fields in China.